Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report
Authors:
Open Access
- 8 December 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1047992
Abstract
Background: Elderly-onset neuromyelitis optica spectrum disorder (NMOSD) is a rare entity that poses a therapeutic challenge. We report a case of elderly-onset NMOSD with mutant FCGR3A genotype who was successfully treated with ofatumumab after multiple episodes of relapse.Case Report: The patient was a 67-year-old woman who was diagnosed with NMOSD with high disease activity. She experienced six episodes of relapse over a period of 2 years despite immunosuppressant therapy with intravenous rituximab (RTX), oral steroids, mycophenolate mofetil, and tacrolimus. At the last relapse, she was unable to walk and developed immunosuppressant-induced hypogammaglobulinemia. Based on the insufficient B cell depletion and FCGR3A-FF genotype carrier, the patient was diagnosed as RTX non-responder. After subcutaneous ofatumumab plus intravenous immunoglobulin replacement therapy, she was able to walk independently, and experienced no further relapse. Ofatumumab was well-tolerated, and sufficiently depleted the circulating B cells.Conclusion: Ofatumumab might be an effective alternative in RTX-unresponsive NMOSD, and seems to be safe in elderly patients.Keywords
This publication has 7 references indexed in Scilit:
- Very late onset neuromyelitis optica spectrum disordersEuropean Journal of Neurology, 2021
- Ofatumumab versus Teriflunomide in Multiple SclerosisNew England Journal of Medicine, 2020
- Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorderNeurology Neuroimmunology & Neuroinflammation, 2020
- Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosisNeurology, 2018
- Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis OpticaJAMA Neurology, 2015
- Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapyAnnals of Hematology, 2011
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood, 2004